medical-aesthetics
(13)
Robert Bestwick Built a Career Between Two Kinds of Attention
From rural Chilean businesses to a Vancouver classroom and an established aesthetics brand, Robert Bestwick’s career is a study in translating attention into useful action.
Vancouver Laser Bet $180,000 on a Machine Nobody Trusted - Then Built a 30-Year Clinic
A floppy disk, a basement phone bank and one C$180,000 laser became a Vancouver clinic built on repeat visits, relentless training and an oddly smart perk: child care while you get treated.
Bausch Health Built a $10 Billion Medicine Cabinet - Now It Has to Outrun a $20 Billion Hangover
Its products sit in pharmacies, dental offices, GI clinics and aesthetics practices across roughly 100 countries. The hard part is not selling medicine - it is turning a sprawling acquisition legacy into a focused healthcare company before debt, patents and price controls set the pace.
The Squash Court Startup Quietly Rolling Up America's Med-Spas
Two Harvard MBAs sketched a med-spa roll-up between squash matches. Six years later, Aesthetic Partners runs the back office for 20-plus clinics - and lets every founder keep their name on the door.
The Beauty Roll-Up That Refuses to Erase the Name on the Door
United Aesthetics Alliance is assembling a national network of plastic surgery practices and medical spas without turning them into a single chain. Its wager is that shared capital, recruiting, marketing, and technology can scale - while clinical judgment and local reputations stay local.
Annie Aesthetic
Annie Aesthetic is a medical-aesthetics holding company that partners with and acquires leading medical spas across the United States. Incubated by Tucker's Farm Corporation in May 2022 with roughly $30 million of equity capital, it provides its partner clinics with growth capital, operations, marketing, recruiting, technology and legal/regulatory support while keeping founders and operating teams in place. By late 2025 the platform had grown to about $65 million of revenue across 12 medical-aesthetics brands, backed by InterAlpen Partners, Brookside Equity Partners and Plexus Capital.
AVAVA, Inc.
AVAVA, Inc. is a Waltham, Massachusetts medical aesthetics company that builds energy-based laser platforms for skin renewal that work across all skin tones. Spun out of Boston-based Blossom Innovations and rooted in research from Massachusetts General Hospital's Wellman Center for Photomedicine, AVAVA's flagship MIRIA Skin Treatment System pairs patented Focal Point Technology with AI-driven skin visualization to deliver precise, high-energy intradermal treatment for conditions like melasma, hyperpigmentation, and acne scars with minimal downtime.
Fount Bio, Inc.
Fount Bio is a Somerville, Massachusetts life-science company that builds long-lasting hyaluronic acid (HA) matrices directly inside living tissue. Its proprietary Flī-HA platform uses Nobel-Prize-winning bioorthogonal (click) chemistry to deliver HA building blocks that self-assemble in situ into a biostable, high-molecular-weight matrix - overcoming the delivery and degradation barriers that have long forced HA to be injected as pre-formed filler. The lead product, Flī-Derm, is a needle-free liquid for aesthetic dermatology that reduced fine lines and wrinkles in a blinded clinical study and won IMCAS 2024's Innovation of the Year. The tunable platform extends toward ophthalmology, joints, mucosal tissue and women's health.
Samuel Schloss
Samuel Schloss is the co-founder and CEO of Annie Aesthetic, a medical-aesthetics platform incubated by Tucker's Farm Corporation that consolidates leading U.S. medspas under one operating umbrella. Since launching in May 2022 with roughly $30 million in seed capital, the company has grown to twelve brands and a $65 million revenue run-rate, closing a Series B in 2025 led by InterAlpen Partners. Schloss came from investment banking and private equity, including Reverence Capital Partners.
PatientFi
PatientFi is a healthcare fintech that lets patients pay for elective medical treatments over time through simple monthly payment plans. Its point-of-sale platform partners with medical practices - across plastic surgery, dermatology, dentistry, ophthalmology, fertility and medical spas - to offer instant, soft-credit-check financing so patients can afford care without upfront strain, while practices grow revenue. Headquartered in Irvine, California, the company markets itself as 'The Friendly Way to Pay.'
Todd Watts
Todd Watts is the co-founder and CEO of PatientFi, an Irvine, California fintech that lets patients pay for elective and out-of-pocket healthcare in monthly installments at the point of care. Since starting the company in 2017, he has built a platform that has helped roughly 320,000 patients qualify for more than $3 billion in care across aesthetics, fertility, dentistry, ophthalmology and audiology, reaching a $140 million annual revenue run rate and 130 employees. A former J.P. Morgan investment banker with a Yale MBA, Watts was named an EY Entrepreneur Of The Year 2024 Pacific Southwest winner.
Chris Boudreaux
Chris Boudreaux is a fintech professional and co-founder associated with Cherry (withcherry.com), a San Francisco-based healthcare financing platform trusted by over 60,000 medical providers across the United States. Cherry enables patients to access flexible, interest-free payment plans for elective medical procedures - dental, plastic surgery, medspas, and veterinary care - while giving providers same-day upfront payment. Based in Chattanooga, Tennessee, Boudreaux operates at the intersection of financial technology and healthcare access, helping expand Cherry's reach across the healthcare provider ecosystem.
Felix Steinmeyer
Felix Steinmeyer is the CEO and Co-Founder of Cherry, the leading buy-now-pay-later platform built specifically for healthcare and wellness providers. A Stanford MBA with dual master's degrees, he previously co-founded and sold Mason Finance before turning his attention to the underserved gap between patients who need care and their ability to pay for it. Under his leadership, Cherry has grown to serve 60,000+ providers, raised a Series B of $44M in 2022, and in April 2025 achieved a valuation exceeding $2 billion with a Series C round - making it one of the most significant vertical BNPL players in healthcare.